文献速递肾移植

肾移植受者中质子泵抑制剂使用、疲劳与健康相关生活质量:TransplantLines生物样本库与队列研究结果

Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2023-02-18

该横断面研究纳入937例肾移植受者,发现质子泵抑制剂使用与疲劳严重程度、严重疲劳风险、较低的身体和心理健康相关生活质量独立相关,且各质子泵抑制剂类型均存在关联并呈剂量依赖性。

要点

  • 质子泵抑制剂使用与肾移植受者疲劳严重程度独立相关(回归系数4.02,95%CI 2.18至5.85,P<0.001)。
  • 质子泵抑制剂使用与严重疲劳风险独立相关(OR 2.05,95%CI 1.48至2.84,P<0.001)。
  • 质子泵抑制剂使用与较低的身体和心理健康相关生活质量独立相关。

核心结论

  • 质子泵抑制剂使用与肾移植受者疲劳及较低健康相关生活质量独立相关。
  • 质子泵抑制剂使用可能是减轻肾移植受者疲劳和改善健康相关生活质量的易于获取的靶点。
  • 需要进一步研究探讨该人群中质子泵抑制剂暴露的影响。

研究设计与样本

  • 横断面研究,纳入TransplantLines生物样本库与队列研究中移植≥1年的肾移植受者937例(平均年龄56±13岁,39%女性),移植后中位时间3(1-10)年。
  • 暴露为质子泵抑制剂使用、类型、剂量及使用时长;结局为疲劳和健康相关生活质量,分别采用经验证的Checklist Individual Strength 20 Revised问卷和Short Form-36问卷评估。
  • 分析采用逻辑回归和线性回归。

主要发现

  • 质子泵抑制剂使用与疲劳严重程度相关(回归系数4.02,95%CI 2.18至5.85,P<0.001)。
  • 质子泵抑制剂使用与严重疲劳风险相关(OR 2.05,95%CI 1.48至2.84,P<0.001)。
  • 质子泵抑制剂使用与较低的身体健康相关生活质量相关(回归系数-8.54,95%CI -11.54至-5.54,P<0.001)。
  • 质子泵抑制剂使用与较低的心理健康相关生活质量相关(回归系数-4.66,95%CI -7.15至-2.17,P<0.001)。
  • 上述关联独立于年龄、移植后时间、上消化道疾病史、抗血小板治疗及药物总数等潜在混杂因素,在所有单独评估的质子泵抑制剂类型中均存在且呈剂量依赖性;质子泵抑制剂暴露时长仅与疲劳严重程度相关。

临床怎么用

  • 原文结论指出质子泵抑制剂使用可能是减轻肾移植受者疲劳和改善健康相关生活质量的易于获取的靶点。
  • 原文结论指出需要进一步研究探讨该人群中质子泵抑制剂暴露的影响。

局限性

  • 残余混杂。
  • 无法评估因果关系。
  • 需要进一步研究探讨该人群中质子泵抑制剂暴露的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Prior studies report that the use of proton pump inhibitors (PPIs) can adversely affect gut microbiota and gastrointestinal uptake of micronutrients, in particular iron and magnesium, and are used frequently by kidney transplant recipients. Altered gut microbiota, iron deficiency, and magnesium deficiency have been implicated in the pathogenesis of chronic fatigue. Therefore, we hypothesized that PPI use may be an important and underappreciated cause of fatigue and reduced health-related quality of life (HRQoL) in this population. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: Kidney transplant recipients (≥1 year after transplantation) enrolled in the TransplantLines Biobank and Cohort Study. EXPOSURE: PPI use, PPI type, PPI dosage, and duration of PPI use. OUTCOME: Fatigue and HRQoL, assessed using the validated Checklist Individual Strength 20 Revised questionnaire and Short Form-36 questionnaire. ANALYTICAL APPROACH: Logistic and linear regression. RESULTS: We included 937 kidney transplant recipients (mean age 56±13 years, 39% female) at a median of 3 (1-10) years after transplantation. PPI use was associated with fatigue severity (regression coefficient 4.02, 95% CI, 2.18 to 5.85, P<0.001), a higher risk of severe fatigue (OR 2.05, 95% CI, 1.48 to 2.84, P<0.001), lower physical HRQoL (regression coefficient-8.54, 95% CI, -11.54 to-5.54, P<0.001), and lower mental HRQoL (regression coefficient-4.66, 95% CI, -7.15 to-2.17, P<0.001). These associations were independent of potential confounders including age, time since transplantation, history of upper gastrointestinal disease, antiplatelet therapy, and the total number of medications. They were present among all individually assessed PPI types and were dose dependent. Duration of PPI exposure was only associated with fatigue severity. LIMITATIONS: Residual confounding and inability to assess causal relationships. CONCLUSIONS: PPI use is independently associated with fatigue and lower HRQoL among kidney transplant recipients. PPI use might be an easily accessible target for alleviating fatigue and improving HRQoL among kidney transplant recipients. Further studies examining the effect of PPI exposure in this population are warranted. PLAIN-LANGUAGE SUMMARY: In this observational study, we investigated the association of proton pump inhibitors with fatigue and health-related quality of life among kidney transplant recipients. Our data showed that proton pump inhibitors were independently associated with fatigue severity, severe fatigue, and lower physical and mental health-related quality of life. These associations were present among all individually assessed proton pump inhibitor types and were dose dependent. While we await future studies on this topic, proton pump inhibitor use might be an easily accessible target for alleviating fatigue and improving health-related quality of life among kidney transplant recipients.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Knobbe TJ, Kremer D, Douwes RM, et al. Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study. Am J Kidney Dis. 2023. PMID: 36801431. doi:10.1053/j.ajkd.2022.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。